Email this article 
Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
- Authors: Shuvaev V.A.1, Fominykh M.S.1, Martynkevich I.S.1, Udaleva V.Y.1, Potikhonova N.A.1, Zenina M.N.1, Abdulkadyrov K.M.1
-
Affiliations:
- Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological Agency
- Issue: Vol 8, No 4 (2013)
- Pages: 7-12
- Section: HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE
- Published: 21.11.2013
- URL: https://oncohematology.abvpress.ru/ongm/article/view/12
- DOI: https://doi.org/10.17650/1818-8346-2013-8-4-7-12
- ID: 12
Cite item
Full Text
Abstract
At present, introduction of target therapy to chronic myelogenous leukemia (CML) treatment made CML not life-limiting disorder. The main condition of treatment efficacy is its continuity. The most common causes of dose reduction and CML therapy interruption is hematologic toxicities such as neutropenia and thrombocytopenia. The adverse events correction in these circumstances is vital. Recommendations for neutropenia and thrombocytopenia correction are proposed in this article. The basement and results of the use of granulocyte colony stimulating factor (G-CSF) and thrombopoietine receptor agonist for hematologic toxicities correction with clinical case are presented.
About the authors
V. A. Shuvaev
Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological AgencyRussian Federation
M. S. Fominykh
Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological Agency
Author for correspondence.
Email: m.s.fominyh@gmail.com
Russian Federation
I. S. Martynkevich
Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological AgencyRussian Federation
V. Y. Udaleva
Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological AgencyRussian Federation
N. A. Potikhonova
Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological AgencyRussian Federation
M. N. Zenina
Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological AgencyRussian Federation
K. M. Abdulkadyrov
Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological AgencyRussian Federation
References
Supplementary files
